T315I is the most common mutation in TKI-resistant CML1-3
Explore T315I mutation in chronic phase chronic myeloid leukemia
Among patients with a BCR::ABL1 mutation,
the frequency of the T315I mutation was 10-27%.2,4-6
the frequency of the T315I mutation was 10-27%.2,4-6
Development of the T315I mutation leads to resistance with 1st- or 2nd-generation TKIs1,7
BCR::ABL1 mutation testing helps inform TKI treatment choice7,8
ICLUSIG is the only 3rd-generation pan-mutational TKI that delivers proven long-term efficacy for patients with a T315I mutation9-11
NCCN Category 2A treatment option in CML based on BCR::ABL1 mutation status7
- Potatinib is a preferred subsequent therapy option for patients with no identifiable BCR::ABL1 mutations:
- Ponatinib is a treatment option for CP-CML with resistance or intolerance to at-least 2 prior TKIs or for patients with AP-CML or BP-CML for whom no other TKI is indicated
- Ponatinib is preferred for patients with AP-CML or BP-CML with a T315I mutation and is a treatment option for patients with this mutation in CP-CML
70% of CP-CML patients with a T315I mutation in the PACE trial (n=64) achieved MCyR, and responses were deep and durable11